An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache

Journal of Clinical Psychiatry

Volumn 69, Issue 9, 2008, Pages 1449-1454

  Volpe, Fernando M ^a,b  

^a Hospital Geral Socor   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; DULOXETINE; PARACETAMOL;

ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PRIMARY HEADACHE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SOMNOLENCE; SWEATING; TENSION HEADACHE; TRANSFORMED MIGRAINE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VISUAL ANALOG SCALE; VOMITING;

EID: 52649086326     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0912     Document Type: Article

References (37)

1. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997;58(suppl 6):26-31
2. Hung CI, Liu CY, Juang YY, et al. The impact of migraine in patients with major depressive disorder. Headache 2006;46:469-477
3. Hung CI, Wang SJ, Hsu KH, et al. Risk factors associated with migraine or chronic daily headache in out-patients with major depressive disorder. Acta Psychiatr Scand 2005;111:310-315
4. Juang KD, Wang SJ, Fuh JL, et al. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000;40:818-823
5. Breslau N, Lipton RB, Stewart WF, et al. Comorbidity of migraine and depression-Investigating potential etiology and prognosis. Neurology 2003;60:1308-1312
6. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
7. Lake AE III, Rains JC, Penzien DB, et al. Headache and psychiatric comorbidity: historical context, clinical implications, and research relevance. Headache 2005;45:493-506
8. Saper JR, Lake AE III, Tepper SJ. Nefazadone for chronic daily headache prophylaxis: an open-label study. Headache 2001;41:465-474
9. Tomkins GE, Jackson JL, O'Malley PG, et al. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001;111:54-63
10. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004 Dec;107(1):44-48
11. Bendsten S, Rigmor J. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004;62:1706-1711
12. Zissis NP, Harmoussi S, Vlaikidis N, et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007;27:315-324
13. Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 2004;50:322-328
14. Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005;21:345-356
15. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar;63(3):225-231
16. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28
17. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004 Apr;65(4):521-530
18. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984
19. Pritchett YL, McCarberg BH, Watkin JG, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med 2007;8:397-409
20. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
21. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):9-160
22. Dratcu L, da Costa Ribeiro L, Calil HM. Depression assessment in Brazil: the first application of the Montgomery-Äsberg Depression Rating Scale. Br J Psychiatry 1987;150:797-800
23. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106
24. Berlim MT, Pavanello DP, Caldieraro MAK, et al. Reliability and validity of the WHOQOL BREF in a sample of Brazilian outpatients with major depression. Qual Life Res 2005;14:561-564
25. Dekte MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
26. Dekte MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr;63(4):308-315
27. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
28. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(suppl 13):30-37
29. Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-348
30. Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 2007;61:1349-1355
31. Sheftell FD, Atlas SJ. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache 2002;42:934-944
32. Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: the evolution from episodic headache to chronic neurologic disease: a proposed classification of patients with headache. Headache 2004;44:426-435
33. Brannan SK, Mallinckrodt CH, Detke MJ, et al. Onset of action of duloxetine 60 mg once-daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005;39:161-172
34. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-416
35. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-1420
36. Dunner DL, Wohlreich MM, Mallinckrodt CH, et al. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res 2005;66:522-540
37. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23983 subjects. Curr Med Res Opin 2007;23:175-184